Am J Transplant, Volume 19, Suppl 3 Archives - Page 38 of 214 - ATC Abstracts

2019 American Transplant Congress
Assessment of the Relationship between Inflammation and Glomerular Filtration Rate
J. B. Ramirez-Gonzalez¹, L. E. Morales-BuenRostro², J. Furuzawa-Carballeda³, L. Garcia-Covarrubias⁴, R. L. Pacheco-Domínguez⁵, R. Durazo-Arvizu⁶, J. Alberu³, E. N. Cuevas-Medina⁷, M. López-Cervantes⁵, R. A. Osorio-Juárez⁵
¹Faculty of Medicine, Public Health Department, Universidad Nacional Autónoma de México, Mexico, Mexico, ²Department of Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Department of Transplantation, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁴Department of Transplantation, Hospital General de México Doctor Eduardo Liceaga, Mexico, Mexico, ⁵Faculty of Medicine, Department of Public Health, Universidad Nacional Autónoma de México, Mexico, Mexico, ⁶Department of Public Health Sciences, Loyola University Chicago, Chicago, IL, ⁷Department of Cardiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico, Mexico
*Purpose: Since the inflammatory phenomena that occur after transplantation are decisive factors for developing renal rejection, we decided to study how the elevation of some…
2019 American Transplant Congress
Dynamic Characterization of Cells in the Perfusate from Cold Ischemic Liver Grafts
R. J. de Vries, C. Pendexter, S. E. Cronin, B. Marques, J. F. Markmann, S. L. Stott, H. Yeh, M. Toner, K. Uygun, S. N. Tessier
Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA
*Purpose: Injury during preservation is a complex process that affects graft function. A deeper understanding and better prediction of liver viability are demanded to improve…
2019 American Transplant Congress
Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody)
S. Ge¹, A. Petrosyan¹, M. Chu¹, N. Ammerman², A. Vo², S. C. Jordan², X. Zhang³, M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, ³HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: IL-6 is a pro-inflammatory cytokine involved in KTx rejection. A clinical trial to improve cABMR using CLZ in HLA-sensitized KTx Pts is underway. Inhibition…
2019 American Transplant Congress
Natural Killer Cells Express Significantly More CD16 during Chronic Active Antibody Mediated Rejection Which is Not Caused by a Single Nucleotide Polymorphism within the CD16 Gene
K. Sablik, N. Litjens, A. Peeters, M. Clahsen-van Groningen, M. Klepper, M. Betjes
Erasmus MC, Rotterdam, Netherlands
*Purpose: Chronic-active antibody mediated rejection (c-aABMR) is the leading cause of long-term renal allograft loss. Fc-receptor CD16 bearing natural killer (NK) cells may be involved…
2019 American Transplant Congress
Management of Inactive Candidates on the Kidney Transplant Waitlist: Results from a National Survey
J. Hiller, J. Chen, K. Covarrubias, K. Jackson, J. Long, S. DiBrito, D. Segev, J. Garonzik Wang
Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: As the inactive deceased donor kidney transplant (DDKT) waitlist pool continues to grow, management of these patients has become an increasingly complex administrative undertaking.…
2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…
2019 American Transplant Congress
Effect of Everolimus on IgM and IgG Memory B Cell Growth and Survival In Vitro and Applications for Effective Administration in Clinical Practice
Y. Matsuda
Osaka University Graduate School of Medicine, Osaka, Japan
*Purpose: Everolimus (EVR), which is converted from CNI, is reported to improve renal function and reduce renal toxicity, DSA production, and rejection development. However, there…
2019 American Transplant Congress
A Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients
T. A. Horwedel¹, C. E. Carthon¹, S. E. January¹, A. Gharabagi¹, R. Delos Santos², J. C. Hagopian¹
¹Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ²Nephrology, Washington University School of Medicine, Saint Louis, MO
*Purpose: Beginning in December 2015, our center instituted a protocol change moving to de novo use of LCPT. The objective of this study is to…
2019 American Transplant Congress
Optimizing Opportunity and Benefits of Steroid Avoidance in the New KAS Era
S. Sultan, M. Aull, R. Friedlander, V. K. Sharma, D. Serur, A. Watkins, S. Kapur, D. Dadhania
New York Presbyterian / Weill Cornell, New York, NY
*Purpose: The introduction of the new Kidney Allocation System (KAS) in 2014 has facilitated transplantation of sensitized patients with high CPRA. However, the CPRA value…
2019 American Transplant Congress
Staged Procedure In Simultaneous Liver And Kidney Transplant -the “Swedish” Experience
A. Gravetz
Transplant Surgery, Swedish Medical Center, Seattle, WA
*Purpose: As many as 30% of liver transplant candidates have renal insufficiency requiring a combined liver and kidney transplantation. The prolonged and complex simultaneous liver-kidney…